Open access
Open access
Powered by Google Translator Translator

Oncology – Breast

Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years

26 Jan, 2023 | 12:04h | UTC

Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right? – Journal of Clinical Oncology

 

Commentary from the author on Twitter

 

RCT | Breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection vs. standard surgical treatment of axilla

24 Jan, 2023 | 14:15h | UTC

Occurrence of breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial – Cancer

 

Commentary on Twitter

 

RCT | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

20 Jan, 2023 | 14:20h | UTC

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Interim Analysis of Overall Survival in the monarchE Trial – The ASCO Post

 

Commentary on Twitter

 

Review | Role of immunotherapy in breast cancer

18 Jan, 2023 | 14:03h | UTC

Role of Immunotherapy in Breast Cancer – JCO Oncology Practice

 

RCT | Cosmetic results and side effects of accelerated partial-breast irradiation vs. whole-breast irradiation for low-risk invasive carcinoma of the breast

15 Jan, 2023 | 19:53h | UTC

Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter

 

ASCO Guideline Update | Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer

13 Jan, 2023 | 13:28h | UTC

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

 

Cohort Study | Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

13 Jan, 2023 | 13:14h | UTC

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 – Journal of Clinical Oncology

Commentary: Incidence of Contralateral Breast Cancers Among Pathogenic Variant Carriers Could Guide Management Decisions – ASCO Daily News

 

Post-trial follow-up | Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer.

15 Dec, 2022 | 13:29h | UTC

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer – Cancer Therapy Advisor

Original Study: Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial – The Lancet

 

Commentary on Twitter

 

Post-trial follow-up | Radiotherapy vs. surgery of the axilla after a positive sentinel node in breast cancer.

14 Dec, 2022 | 14:42h | UTC

Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: ART Preferred Over ALND in Sentinel Node-Positive Early Breast Cancer – Cancer Therapy Advisor

 

RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.

12 Dec, 2022 | 12:40h | UTC

Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

RCT | Trastuzumab deruxtecan vs. trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.

8 Dec, 2022 | 12:49h | UTC

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial – The Lancet

 

Post-trial follow-up | Long-term outcomes of adjuvant denosumab in breast cancer.

22 Nov, 2022 | 13:14h | UTC

Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer – NEJM Evidence 

Original Study: Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text) 

 

18F-sodium fluoride PET–CT vs. 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer.

22 Nov, 2022 | 13:09h | UTC

Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text) 

Commentary: 18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis – Cancer Therapy Advisor 

 

Cohort Study | Use of breast cancer risk factors may identify risk-adapted starting age of screening.

18 Nov, 2022 | 13:16h | UTC

Use of Breast Cancer Risk Factors to Identify Risk-Adapted Starting Age of Screening in China – JAMA Network Open

Invited Commentary: Risk-Based Approaches to Breast Cancer Screening in China – JAMA Network Open

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1590766235989708801

 

Phase 2 RCT | Non-hormonal drug reduces vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.

15 Nov, 2022 | 12:58h | UTC

Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial – The Lancet

Commentary: Non-hormonal therapy reduces hot flashes and night sweats in women who have been diagnosed with breast cancer – Monash University 

 

RCT | Comparison of acupuncture vs. sham acupuncture in the treatment of aromatase inhibitor–related joint pain.

15 Nov, 2022 | 12:47h | UTC

Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain: A Randomized Clinical Trial – JAMA Network Open

Commentary: Aromatase inhibitors and acupuncture in breast cancer: Spinning a negative study, four years later – Science-based Medicine

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1591113526222913538

 

Cohort Study | Association of Taxane type with chemotherapy-induced peripheral neuropathy in patients with breast cancer.

4 Nov, 2022 | 13:15h | UTC

Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer – JAMA Network Open 

 

Single-arm P2 study | Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy.

2 Nov, 2022 | 14:23h | UTC

Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Some breast cancer patients with high responses to chemotherapy may not need surgery: Biopsy protocol identifies patients at low risk of recurrence – University of Texas M. D. Anderson Cancer Center

Commentary: Elimination of Surgery Explored for Selected Breast Cancer Patients – HealthDay

 

Commentary on Twitter

 

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.

31 Oct, 2022 | 13:50h | UTC

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline – Annals of Oncology

 

Nonsurgical options for risk reduction of contralateral breast cancer in BRCA mutation carriers with early breast cancer.

31 Oct, 2022 | 13:41h | UTC

Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer – Journal of Clinical Oncology (free for a limited period)

 

Guideline | Reporting of surgically removed lymph nodes for breast tumors.

25 Oct, 2022 | 13:20h | UTC

Reporting of Surgically Removed Lymph Nodes for Breast Tumors: Recommendations From the International Collaboration on Cancer Reporting – Archives of Pathology & Laboratory Medicine

 

Cohort Study | Systemic or vaginal hormone therapy after early breast cancer.

24 Oct, 2022 | 14:00h | UTC

Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study – JNCI: Journal of the National Cancer Institute

News Release: Hormone replacement therapy doesn’t lead to breast cancer reoccurrence – Oxford University Press

Commentaries:

Expert reaction to study looking at menopausal hormone therapy after early-stage breast cancer, and breast cancer recurrence – Science Media Centre

Hormone Replacement Therapy Won’t Raise Recurrence Rate for Breast Cancer Survivors – HealthDay

 

Post-trial follow-up | Adjuvant Olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.

17 Oct, 2022 | 12:27h | UTC

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer – Annals of Oncology

Original Study: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

Images under a Creative Commons Attribution (CC BY 4.0) license

 

Recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.

14 Oct, 2022 | 14:12h | UTC

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022 – Breast Care

See also: Advanced Breast Cancer: AGO Recommendations 2022 – Focus on ABC6 Consensus – Geburtshilfe und Frauenheilkunde

 

Cohort Study | Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors.

14 Oct, 2022 | 14:03h | UTC

Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study – Journal of Clinical Oncology

News Release: Long-term study supports link between inflammation and cognitive problems in older breast cancer survivors – University of California

 

Stay Updated in Your Specialty

No spam, just news.